Substance / Medication

Diltiazem hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Topical diltiazem hydrochloride and glyceryl trinitrate in the treatment of chronic anal fissure.
Jawaid Masood, Masood Zubia, Salim Manzar · J Coll Physicians Surg Pak · 2009
PMID: 19811710RCT
In vitro and in vivo evaluation of guar gum matrix tablets for oral controlled release of water-soluble diltiazem hydrochloride.
Al-Saidan Saleh M, Krishnaiah Yellela S R, Patro Srinivas S et al. · AAPS PharmSciTech · 2005
PMID: 16353958ObservationalFull text (PMC)
Preparation and evaluation of diltiazem hydrochloride-Gelucire 43/01 floating granules prepared by melt granulation.
Shimpi Shyam, Chauhan Bhaskar, Mahadik K R et al. · AAPS PharmSciTech · 2004
PMID: 15760076ObservationalFull text (PMC)
Near-infrared FT-Raman spectroscopy as a rapid analytical tool for the determination of diltiazem hydrochloride in tablets.
Vergote Geert J, Vervaet Chris, Remon Jean Paul et al. · Eur J Pharm Sci · 2002
PMID: 12113892Observational
Facial hyperpigmentation caused by diltiazem hydrochloride.
Desai Nina, Alexis Andrew F, DeLeo Vincent A · Cutis · 2010
PMID: 20919601Case Report
A case of lichenoid purpura possibly caused by diltiazem hydrochloride.
Inui S, Itami S, Yoshikawa K · J Dermatol · 2001
PMID: 11320702Case Report
Controlled Release Technologies for Diltiazem Hydrochloride: A Comprehensive Review of Solid Dosage Innovations.
Troches-Mafla Estefanía, Salamanca Constain H, Ciro Yhors · Pharmaceutics · 2025
PMID: 41304827ReviewFull text (PMC)
Diltiazem Hydrochloride Floating Matrix Tablet: Formulation andEvaluation.
Koradia Krishna D, Jotaniya Bhavin K, Koradia Hiral D · Cardiovasc Hematol Disord Drug Targets · 2024
PMID: 39034726Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Diltiazem hydrochloride (substance)
SNOMED CT
12218006
UMLS CUI
C0700579

Clinical Data

This intervention maps to 15 entities in the Ltrl knowledge graph.

6
Conditions
4
Biomarkers
3
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.